Matches in SemOpenAlex for { <https://semopenalex.org/work/W4294636964> ?p ?o ?g. }
- W4294636964 abstract "Abstract Background Single-agent immunotherapy is currently the recommended second-line therapy for patients with advanced non–small cell lung cancer (NSCLC) without targetable mutations; however, the objective response rate (ORR) remains low. This phase II study evaluated the efficacy of the combination therapy of sintilimab plus docetaxel and explored potential biomarkers for efficacy prediction. Methods Thirty patients with NSCLC without targetable mutations whose disease progressed from first-line platinum-based chemotherapy from October 2019 to December 2020 were enrolled in this single-arm, single-center, phase II trial. Sintilimab (200 mg) and docetaxel (75 mg/m 2 ) were administered every 3 weeks until progression. The primary endpoint was ORR. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and safety. Biomarker analyses of blood and tissue samples were also performed. Results Among 30 patients, 11 patients had partial response, resulting in an ORR of 36.7%. The median PFS was 5.0 months (95%CI: 3.9–6.1) and OS was 13.4 months (95%CI: 5.6–21.2). The most common immune-related adverse event of any grade was hepatitis, observed in 23.3% (7/30) of patients. Treatment-emergent adverse events were manageable. Patients detected with high PD-L1 expression in circulating tumor cells (cutoff value ≥32.5% based on the median CTC-PD-L1 expression) achieved significantly higher ORR (60% versus 13.3%, p = 0.021) and significantly longer median PFS (6.0 versus 3.5 months, p = 0.011) and median OS (15.8 versus 9.0 months, p = 0.038) than those with low CTC-PD-L1 level. Patients detected with PD-L1 < 1% and CD8 ≥ 1% expression from their baseline tissue samples had significantly higher ORR (83.3% versus 12.5%, p = 0.026) but similar PFS ( p = 0.62) and OS ( p = 0.15). Conclusion This study demonstrated the effectiveness and safety of sintilimab plus docetaxel as a second-line treatment of NSCLC without targetable mutations after progression from first-line platinum-based chemotherapy. Trial registration This study was registered in the Clinical trials registry with ClinicalTrials.gov Identifier NCT03798743 (SUCCESS)." @default.
- W4294636964 created "2022-09-05" @default.
- W4294636964 creator A5012598663 @default.
- W4294636964 creator A5014707193 @default.
- W4294636964 creator A5033825363 @default.
- W4294636964 creator A5036139505 @default.
- W4294636964 creator A5037953219 @default.
- W4294636964 creator A5048151775 @default.
- W4294636964 creator A5058391979 @default.
- W4294636964 creator A5062852782 @default.
- W4294636964 creator A5063481044 @default.
- W4294636964 creator A5076756498 @default.
- W4294636964 creator A5082825584 @default.
- W4294636964 creator A5086860197 @default.
- W4294636964 date "2022-09-05" @default.
- W4294636964 modified "2023-10-16" @default.
- W4294636964 title "Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study" @default.
- W4294636964 cites W1889335134 @default.
- W4294636964 cites W1917588793 @default.
- W4294636964 cites W1978857579 @default.
- W4294636964 cites W2019607817 @default.
- W4294636964 cites W2051940153 @default.
- W4294636964 cites W2074378511 @default.
- W4294636964 cites W2104347254 @default.
- W4294636964 cites W2113464761 @default.
- W4294636964 cites W2124837959 @default.
- W4294636964 cites W2140980839 @default.
- W4294636964 cites W2156353875 @default.
- W4294636964 cites W2170030318 @default.
- W4294636964 cites W2228221433 @default.
- W4294636964 cites W2397958390 @default.
- W4294636964 cites W2405058420 @default.
- W4294636964 cites W2535300095 @default.
- W4294636964 cites W2572174216 @default.
- W4294636964 cites W2590151798 @default.
- W4294636964 cites W2743368676 @default.
- W4294636964 cites W2791753645 @default.
- W4294636964 cites W2796582438 @default.
- W4294636964 cites W2890844400 @default.
- W4294636964 cites W2904211489 @default.
- W4294636964 cites W2904835427 @default.
- W4294636964 cites W2914427235 @default.
- W4294636964 cites W2925446385 @default.
- W4294636964 cites W2961686530 @default.
- W4294636964 cites W2967960429 @default.
- W4294636964 cites W2979620384 @default.
- W4294636964 cites W3011900210 @default.
- W4294636964 cites W3015756332 @default.
- W4294636964 cites W3016686675 @default.
- W4294636964 cites W3047859155 @default.
- W4294636964 cites W3108515906 @default.
- W4294636964 cites W3111549528 @default.
- W4294636964 cites W3111665711 @default.
- W4294636964 cites W3120933346 @default.
- W4294636964 cites W3138023380 @default.
- W4294636964 cites W3144903047 @default.
- W4294636964 cites W3164993995 @default.
- W4294636964 cites W3165007730 @default.
- W4294636964 cites W3175170112 @default.
- W4294636964 cites W3187725522 @default.
- W4294636964 cites W3191795128 @default.
- W4294636964 cites W3200816639 @default.
- W4294636964 cites W3201444057 @default.
- W4294636964 cites W3204445415 @default.
- W4294636964 cites W4200204256 @default.
- W4294636964 cites W4223498941 @default.
- W4294636964 cites W4224987101 @default.
- W4294636964 cites W4280522696 @default.
- W4294636964 cites W4281632294 @default.
- W4294636964 cites W4283386348 @default.
- W4294636964 doi "https://doi.org/10.1186/s12885-022-10045-0" @default.
- W4294636964 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36064386" @default.
- W4294636964 hasPublicationYear "2022" @default.
- W4294636964 type Work @default.
- W4294636964 citedByCount "6" @default.
- W4294636964 countsByYear W42946369642022 @default.
- W4294636964 countsByYear W42946369642023 @default.
- W4294636964 crossrefType "journal-article" @default.
- W4294636964 hasAuthorship W4294636964A5012598663 @default.
- W4294636964 hasAuthorship W4294636964A5014707193 @default.
- W4294636964 hasAuthorship W4294636964A5033825363 @default.
- W4294636964 hasAuthorship W4294636964A5036139505 @default.
- W4294636964 hasAuthorship W4294636964A5037953219 @default.
- W4294636964 hasAuthorship W4294636964A5048151775 @default.
- W4294636964 hasAuthorship W4294636964A5058391979 @default.
- W4294636964 hasAuthorship W4294636964A5062852782 @default.
- W4294636964 hasAuthorship W4294636964A5063481044 @default.
- W4294636964 hasAuthorship W4294636964A5076756498 @default.
- W4294636964 hasAuthorship W4294636964A5082825584 @default.
- W4294636964 hasAuthorship W4294636964A5086860197 @default.
- W4294636964 hasBestOaLocation W42946369641 @default.
- W4294636964 hasConcept C126322002 @default.
- W4294636964 hasConcept C143998085 @default.
- W4294636964 hasConcept C185592680 @default.
- W4294636964 hasConcept C197934379 @default.
- W4294636964 hasConcept C203092338 @default.
- W4294636964 hasConcept C2776256026 @default.
- W4294636964 hasConcept C2776694085 @default.
- W4294636964 hasConcept C2779984678 @default.
- W4294636964 hasConcept C2780739268 @default.